SML3467

Remimazolam

≥98% (HPLC)

• 别名: (S)-Methyl 3-(8-bromo-1-methyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl)propanoate, CNS 7054 methyl ester, CNS 7056, CNS-7054 methyl ester, CNS-7056, CNS7054 methyl ester, CNS7056, Methyl 3-{(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl}propanoate, ONO 2745, ONO-2745, ONO2745
• 经验公式（希尔记法）: C₂₁H₁₉BrN₄O₂
• CAS号: 308242-62-8
• 分子量: 439.31
• MDL编号: MFCD18633229
• UNSPSC代码: 12352200

属性

• 质量水平: 100
• 方案: ≥98% (HPLC)
• 表单: powder
• 药品控制: USDEA Schedule IV
• 颜色: white to beige
• 溶解性: DMSO: 2 mg/mL, clear
• 储存温度: -10 to -25°C
• SMILES字符串: CC1=CN=C2[C@H](CCC(OC)=O)N=C(C3=CC=CC=N3)C4=CC(Br)=CC=C4N12
• InChI: 1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1
• InChI key: CYHWMBVXXDIZNZ-KRWDZBQOSA-N

说明

生化/生理作用

GABAA receptor positive allosteric modulator (PAM) that causes fast onset and short duration of sedative action in vivo with rapid recovery.

Remimazolam (CNS 7056) is a benzodiazepine derivative with positive allosteric modulator (PAM) activity toward γ-aminobutyric acid type A (GABAA) receptor (pKi = 7.53/7.50/7.56 against 2.5 nM flunitrazepam for binding human/rat/yucatan micropig brain homogenates; pEC50/Emax = 6.44/375% (α1β2γ2), 6.18/186% (α2β2γ2), 6.04/210% (α3β2γ2), 5.86/289% (α5β2γ2s) by whole cell patch clamp using cells expressing respective rat αβγ complex). Intravenous injection (25 mg/kg rats, 15-30 mg/kg mice) causes fast onset and short duration of sedative action with rapid recovery when compared with midazolam.

安全信息

• 象形图: GHS07
• 警示用语：: Warning
• 危险声明: H336
• 预防措施声明: P261 - P271 - P304 + P340 + P312 - P403 + P233 - P405 - P501
• 危险分类: STOT SE 3
• 靶器官: Respiratory system
• 储存分类代码: 11 - Combustible Solids
• WGK: WGK 3
• 闪点(°F): Not applicable
• 闪点(°C): Not applicable